HBM Holdings Limited Stock

Hbm Holdings Ltd is an investment holding company mainly engaged in the business of developing therapeutics in the fields of immuno-oncology and immunology diseases. The Company's products include HBM9161, HBM4003, HBM7008 and HBM1020. Batoclimab (HBM9161) is mainly used for immune thrombocytopenia (ITP), graves’ ophthalmopathy (GO), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD). Tanfanercept (HBM9036) is mainly used for dry eye disease (DED). The Company also researches and develops immuno-oncology portfolio, including internally developed next generation immune-oncology assets targeting immune-desert, immune-excluded and inflamed tumors. The Company owns Harbour Mice Platform, generating fully human monoclonal antibodies in the classical two heavy and two light chain H2L2 format as well as heavy chain only (HCAb) format.